The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets), currently under investigation for first-line use in ...
Insilico announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback